Trial · NCT00754832

American Ginseng Treatment for Multiple Sclerosis Related Fatigue

NCT00754832, Phase 2, Completed, Oregon Health and Science University; results first posted 2012-01-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. American Ginseng Treatment for Multiple Sclerosis Related Fatigue. Trials, record NCT00754832. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00754832

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: American Ginseng Treatment for Multiple Sclerosis Related Fatigue
NCT number: NCT00754832
Status: Completed
Phases: Phase 2
Enrollment: 56 participants, actual
Lead sponsor: Oregon Health and Science University
Conditions: Multiple Sclerosis
Interventions: American ginseng extract HT-1001, placebo
First posted: 2008-09-18
Last updated: 2012-01-24
Results first posted: 2012-01-24

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Fatigue Severity Scale	after 6 weeks of intervention	The Fatigue Severity Scale (FSS)is a self-administered instrument that includes 9 items rated on a 7-point scale, measuring fatigue severity. The subject is asked to score each statement, based on how the statement applied to them over the preceding week. The fatigue severity score is the average of the scores on the 9 questions; scores range from 1-7, with lower scores indicating less fatigue.
Secondary	Modified Fatigue Impact Scale	6 weeks of intervention	21 item scale, score range 0-84, lower scores indicate less fatigue
Secondary	Realtime Digital Fatigue Score	6 weeks of intervention	fatigue scored on 0-10 scale with higher scores indicating more fatigue

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Fatigue Severity Scale	after 6 weeks of intervention	intention to treat	units on a scale	MEAN
SECONDARY	Modified Fatigue Impact Scale	6 weeks of intervention		units on a scale	MEAN
SECONDARY	Realtime Digital Fatigue Score	6 weeks of intervention		units on a scale	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Fatigue Severity Scale	Ginseng	5.5	Standard Deviation 1.3	units on a scale
Fatigue Severity Scale	Placebo	5.5	Standard Deviation 1.3	units on a scale
Modified Fatigue Impact Scale	Ginseng	42.7	Standard Deviation 15.7	units on a scale
Modified Fatigue Impact Scale	Placebo	43.7	Standard Deviation 16.7	units on a scale
Realtime Digital Fatigue Score	Ginseng	4.2	Standard Deviation 1.6	units on a scale
Realtime Digital Fatigue Score	Placebo	4.2	Standard Deviation 1.8	units on a scale

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First 6 Weeks Intervention	STARTED	Ginseng First Then Placebo	26
First 6 Weeks Intervention	STARTED	Placebo First Then Ginseng	30
First 6 Weeks Intervention	COMPLETED	Ginseng First Then Placebo	18
First 6 Weeks Intervention	COMPLETED	Placebo First Then Ginseng	28
First 6 Weeks Intervention	NOT COMPLETED	Ginseng First Then Placebo	8
First 6 Weeks Intervention	NOT COMPLETED	Placebo First Then Ginseng	2
2 Weeks Washout	STARTED	Ginseng First Then Placebo	18
2 Weeks Washout	STARTED	Placebo First Then Ginseng	28
2 Weeks Washout	COMPLETED	Ginseng First Then Placebo	17
2 Weeks Washout	COMPLETED	Placebo First Then Ginseng	26

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	rash	Skin and subcutaneous tissue disorders	Ginseng	3	56
other	rash	Skin and subcutaneous tissue disorders	Placebo	0	56
other	insomnia	Psychiatric disorders	Ginseng	3	56
other	insomnia	Psychiatric disorders	Placebo	4	56
other	headache	Nervous system disorders	Ginseng	3	56
other	headache	Nervous system disorders	Placebo	1	56
other	nausea	Gastrointestinal disorders	Ginseng	4	56
other	nausea	Gastrointestinal disorders	Placebo	4	56
other	flu like syndrome	General disorders	Ginseng	3	56
other	flu like syndrome	General disorders	Placebo	2	56

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ginseng
Total, all-cause mortality	Placebo
Total, other adverse events	Ginseng	5	56
Total, other adverse events	Placebo	4	56
Total, serious adverse events	Ginseng	0	56
Total, serious adverse events	Placebo	0	56

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20803391	DERIVED	PubMed
21803872	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Ginseng vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00754832

GET https://conductscience.org/api/trials/v1/NCT00754832/registered

API reference For AI assistants